Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda

 Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda

Promega Signs a Worldwide Agreement with Merck to Develop MSI Technology as CDx for Keytruda

Shots:

  • Promega and Merck collaborated to develop Promega’s microsatellite instability (MSI) technology as an on-label solid tumor CDx for use with Merck’s Keytruda (pembrolizumab)
  •  Promega’s Microsatellite Instability technology measures the genomic accumulation of insertion or deletion (INDEL) errors caused by a deficient mismatch-repair system (dMMR) occurring in a solid-tumors, used to characterize tumors and guide therapeutic choices for MSI-High cancer types
  • The global companies will initially pursue approval for Promega MSI CDx in the US & China. Additionally, Promega intend to get approval for its MSI in IVD test with its anticipated launch in H1’20 in the US, China & EU

Click here to­ read full press release/ article | Ref: Business wire | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post